Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
41.07
+0.92 (2.29%)
At close: Mar 9, 2026, 4:00 PM EDT
41.36
+0.29 (0.71%)
After-hours: Mar 9, 2026, 7:24 PM EDT
Spyre Therapeutics Employees
Spyre Therapeutics had 102 employees as of December 31, 2025. The number of employees increased by 37 or 56.92% compared to the previous year.
Employees
102
Change (1Y)
37
Growth (1Y)
56.92%
Revenue / Employee
n/a
Profits / Employee
-$1,240,608
Market Cap
3.23B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Xenon Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 182 |
| Edgewise Therapeutics | 146 |
SYRE News
- 3 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 13 days ago - Spyre Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 18 days ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - GlobeNewsWire
- 2 months ago - Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
- 4 months ago - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - GlobeNewsWire
- 4 months ago - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire